Pharmacokinetics, tissue residues of tilmicosin phosphate (tilmicor-al®) and its in vitro and in vivo evaluation for the control of Mycoplas-ma gallisepticum infection in broiler chickens


  • Mohamed Elbadawy Lecturer of Pharmacology Department, Faculty of Veterinary Medicine, Benha University
  • Mohamed Aboubakr Lecturer of Pharmacology Department, Faculty of Veterinary Medicine, Benha University





Broilers, Efficacy, Mycoplasma, Pharmacokinetics, Residues, Tilmicosin.


The aim of present study was to determine the pharmacokinetics and tissue residues of tilmicosin phosphate (tilmicoral®) as well as its in vitro and in vivo evaluation for control of Mycoplasma gallisepticum (MG) infection in broiler chickens. Pharmacokinetics (single oral dose) and tissues residues (daily for five days) of tilmicosin (25 mg/kg b.wt) in broilers were investigated. Peak plasma concentration of tilmicosin was 1.25±0.0.09 μg/mL and achieved at 3.15±0.34 h. Elimination half-life was long (44.3±7.22 h) and Vdarea was large (1.25±0.082 L/kg). Residue study revealed a good distribution and penetration of tilmicosine in lung, liver, kidney and muscles. Tilmicosin could not be detected in all tested tissues (except in lung) at 6 days after last administration. The MIC of tilmicosin and tylosin against MG were 0.054 and 0.319 μg/mL, respectively. MG infected chickens and treated by tilmicosin or tylosin showed a significant (p<0.05) improvement in mean body weights gain and a significant (p<0.05) decline in mean clinical signs score, air sac lesion score and mortality rate, however tilmicosin was a superior drug. In conclusion, timicoral® was a very effective medication for controlling MG infection in broiler chickens due to its rapid absorption, long elimination half-life, rapid and extensive penetration from blood into tissues especially lungs and air sacs. Additionally, tilmicoral® had a short withdrawal time. Moreover, its superior efficacy (in vitro and in vivo) against MG.


[1] Abd El-Ghany W A (2009) the in-vitro and in-vivo evaluation of tiamulin and tilmicosin for the treatment of Mycoplasma gallisepticum infected broiler chickens. International Journal of Poultry Science 8, 1189-1198.

[2] Abu-Basha EA, Idkaidek NM & Al-Shunnaq AF (2007) Pharmacokinetics of tilmicosin (Provitil powder and pulmotil liquid AC) oral formulations in chickens. Veterinary Research Communications 31, 477-485. DOI: 10.1007/s11259-006-3543-6

[3] Arret B, Johnson DP & Kirshbaum A (1971) Outline of details for microbiological assays of antibiotics: second revision, Journal of Pharmaceutical Sciences 60, 1689-1694.

[4] Charleston B, Gate JJ, Aitken IA & Reeve-Johnson L (1998) Assessment of the efficacy of tilmicosin as a treatment for Mycoplasma gallisepticum infections in chickens. Avian Pathology 27, 190-195.

[5] Christodoulopoulos G, Warnick LD, Papaioannou N & Fthenakis GC (2002) Tilmicosin administration to young lambs with respiratory infection: safety and efficacy considerations. Journal of Veterinary Pharmacology and Therapeutics 25, 393–397. DOI:10.1046/j.1365-2885.2002.00433.x.

[6] Clark C, Woodbury M, Dowling P, Ross S & Boison JO (2004) A preliminary investigation of the disposition of tilmicosin residues in elk tissues and serum. Journal of Veterinary Pharmacology and Therapeutics 27, 385-387. DOI: 10.1111/j.1365-2885.2004.00609.x.

[7] DeRosa DC, Veenhuizen MF, Bade DJ & Shryock TR (2000) In vitro susceptibility of porcine respiratory pathogens to tilmicosin. Journal of Veterinary Diagnostic Investigation 2, 541-546.

[8] EMEA (1998) The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit, Committee for veterinary medicinal products. Tilmicosin (extension to chicken), summary report 2.

[9] Frey ML, Hanson RP & Andrson DP (1968) A medium for the isolation of avian mycoplasmas. American Journal of Veterinary Research 29, 2163-2171.

[10] Gibaldi M & Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York.

[11] Hoar BR, Jelinski MD, Ribble CS, Janzen ED & Johnson JC (1998) A comparison of the clinical field efficacy and safety of florfenicol and tilmicosin for the treatment of undifferentiated bovine respiratory disease of cattle in western Canada. Candian Veterinary Journal 39, 161-166.

[12] Jordan FTW, Forrester CA, Hodge A & Reeve-Johonson LG (1999) The comparison of an aqueous preparation of tilmicosin with tylosin in the treatment of Mycoplasma gallisepticum infection of turkey poults. Avian Diseases 43, 521-525. DOI: 10.2307/1592651.

[13] Jordan FT & Horrocks BK (1996) the minimum inhibitory concentration of tilmicosin and tylosin for Mycoplasma gallisepticum and Mycoplasma synoviae and a comparison of their efficacy in the control of Mycoplasma gallisepticum infection in broiler chicks. Avian Diseases 40, 326-334. DOI: 10.2307/1592228.

[14] Keles O, Bakirel T & Sener S (2001) Pharmacokinetics and tissue levels of tilmicosin in fowls. Turkish Journal of Veterinary and Animal Sciences 25, 629-634.

[15] Kempf I, Gesbert F, Guittet M & Bennejean G (1994) Mycoplasma gallisepticum infection in medicated chickens: Comparison of diagnosis methods including polymerase chain reaction. Journal of Veterinary Medicine 41, 597-602.

[16] Kempf I, Reeve-Johnson L, Gesbert F & Guittet M (1997) Efficacy of tilmicosin in the control of experimental Mycoplasma gallisepticum infection in chickens. Avian Diseases 41, 802-807. DOI: 10.2307/1592332.

[17] Kempf I, Van Den Hoven R, Gesbert F & Guittet M (1998) Efficacy of difloxacin in broiler chickens for the control of infection due to pathogenic Mycoplasma gallisepticum. Journal of Veterinary Medicine B 45, 305-310.

[18] Kleven SH, King DD & Andreson DP (1972) Airsacculitis in broilers from Mycoplasma gallisepticum: Effect on air-sac lesions of vaccinating with infectious bronchitis and Newcastle virus. Avian Diseases16, 915-924.

[19] Main BW, Means JR, Rinkema LE, Smith WC & Sarazan RD (1996) cardiovascular effects of the macrolide antibiotic tilmicosin, administered alone and in combination with propranolol or dobutamine, in conscious unrestrained dogs. Journal of Veterinary Pharmacology and Therapeutics 19, 225-232.

[20] Modric S, Webb AI & Derendorf H (1998) Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattle. Journal of Veterinary Pharmacology and Therapeutics 21, 444-452.


[22] Modric S, Webb AI & Davidson M (1999) Effect of respiratory tract disease on pharmacokinetics of tilmicosin in rats. Laboratory Animal Science 49, 248-253.

[23] Moore GM, Basson RP & Tonkinson LV (1996) Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine. American Journal of Veterinary Research 57, 224-228.

[24] Papich MG & Riviere JE (2001) Chloramphenicol and derivatives, macrolides, lincosamides and miscellaneous antimicrobials. Veterinary Pharmacology and Therapeutics, 8th edn (Iowa State Press, Ames, IA), pp. 880-881.

[25] Prescott JF (2000) Macrolides and pleuromyilins. Antimicrobial Therapy in Veterinary Medicine, 3rd edn (Iowa State University Press, Ames, IA), pp. 229-262.

[26] Ramadan A (1997) Pharmacokinetics of tilmicosin in serum and milk of goats. Research in Veterinary Science 62, 48-50.

[27] Scorneaux B & Shryock TR (1998a) Intracellular accumulation, subcellular distribution, and efflux of tilmicosin in chicken phagocytes. Poultry Science 77, 1510-1521. DOI:10.1093/ps/77.10.1510

[28] Scorneaux B & ShryockTR (1998b) Intracellular accumulation, subcellular distribution and efflux of tilmicosin in swine phagocytes. Journal of Veterinary Pharmacology and Therapeutics 21, 257-268. DOI: 10.1046/j.1365-2885.1998.00133.x.

[29] Shen J, Li C, Jiang H, Zhang S, Guo P, Ding S & Li X (2005) Pharmacokinetics of tilmicosin after oral administration in swine. American Journal of Veterinary Research 66, 1071-1074. doi:10.2460/ajvr.2005.66.1071

[30] Shryock TR, Klink PR, Readnour RS & Tonkinson LV (1994) Effect of bentonite incorporated in a feed ration with tilmicosin in the prevention of induced Mycoplasma gallisepticum airsacculitis in broiler chickens. Avian Diseases 38, 501-505. DOI: 10.2307/1592071

[31] Snedecor GW & Cochran WG (1980) Statistical Methods. 7th edn., Iowa State College Press, Ames, IA, pp. 39-63.

[32] Stipkovits L, Laber G & Schultze E (1977) Prophylactical and therapeutical efficacy of tiamuline in mycoplasmosis of chickens and turkeys. Poultry Science 56, 1209-1215.

[33] Varga J, Fodor L & Makrai L (2001) Characterisation of some Ornithobacterium rhinotracheale strains and examination of their transmission via eggs. Acta Veterinaria Hungarica 49, 125-130.

[34] Warren MJ, Peters AR, Brett TR & Stoker J (1997) Lung and air sac concentrations of tilmicosin following oral administration of chickens. Journal of Veterinary Pharmacology and Therapeutics 20, 195-196.

[35] Watkins KL, Shryock TR, Dearth RN & Saif YM (1997) In-vitro antimicrobial susceptibility of Clostridium perfringens from commercial turkey and broiler chicken origin. Veterinary Microbiology 54, 195-200.

[36] Whithear KG, Bowtell E & Hughes KL (1983) Evaluation and use of micro broth dilution, procedure for testing sensitivity of fermentative avian mycoplasmas to antibiotics. Avian Diseases 4, 937-949. DOI: 10.2307/1590195.

[37] Zhang Y, Jiang H, Jin X, Shen Z, Shen J, Fu C & Guo J (2004) Residue depletion of tilmicosin in chicken tissues. Journal of Agricultural and Food Chemistry 5, 2602-2605.

[38] Ziv G (1980) Preliminary clinical pharmacological investigations of tylosin and tiamulin in chickens. Veterinary Quarterly, 2:4, 206-210.

[39] Ziv G, Shem-Tov M, Glickman A, Winkler M & Saran A (1995) Tilmicosin antibacterial activity and pharmacokinetics in cows. Journal of Veterinary Pharmacology and Therapeutics 18, 340-345. DOI: 10.1111/j.1365-2885.1995.tb00601.x.

View Full Article: